Comparative Pharmacology
Head-to-head clinical analysis: AVANDIA versus SYNJARDY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDIA versus SYNJARDY XR.
AVANDIA vs SYNJARDY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver.
Synjardy XR is a combination of empagliflozin, an SGLT2 inhibitor that reduces renal glucose reabsorption, and metformin, an AMPK activator that decreases hepatic glucose production and improves insulin sensitivity.
Initial dose 4 mg orally once daily; may increase to 8 mg once daily or 4 mg twice daily if inadequate glycemic control after 8-12 weeks. Maximum dose 8 mg/day.
Initial dose: 5 mg empagliflozin/500 mg metformin extended-release orally twice daily with meals. Titrate based on glycemic control and tolerability up to maximum 25 mg empagliflozin/1000 mg metformin XR twice daily.
None Documented
None Documented
3-4 hours (terminal elimination half-life). No clinically significant accumulation with once-daily dosing.
Empagliflozin: Terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: Terminal half-life ~6.2 hours (plasma); elimination half-life prolonged in renal impairment (up to 17.6 hours in patients with reduced GFR).
Primarily hepatic metabolism via CYP2C8, with minimal renal excretion of unchanged drug (<1%). Approximately 64% of the dose is excreted in urine as metabolites and 23% in feces as metabolites.
Empagliflozin: Approximately 54% excreted unchanged in urine, 41% in feces (metabolites). Metformin: ~90% excreted unchanged in urine via tubular secretion and glomerular filtration; renal clearance ~510 mL/min.
Category C
Category C
Antidiabetic
Antidiabetic